Yordanov Angel, Vasileva-Slaveva Mariela, Galai Noya, Faraggi David, Kubelac Milan Paul, Tripac-Iacovleva Irina, Calleja Neville, Di Fiore Riccardo, Calleja-Agius Jean
Department of Gynecological Oncology, Medical Universiy Pleven, 5800 Pleven, Bulgaria.
Department of Breast Surgery, "Dr. Shterev" Hospital, 1330 Sofia, Bulgaria.
Healthcare (Basel). 2023 Jan 20;11(3):318. doi: 10.3390/healthcare11030318.
Eastern Europe continues to have the highest rates of cancer of the uterine cervix (CUC) and human papillomavirus (HPV) infection in Europe.
The aim of this study was to investigate CUC trends in Bulgaria in the context of a lack of a population-based screening program and a demographic crisis.
This was a retrospective study of 7861 CUC patients who were registered in the Bulgarian National Cancer Registry (BNCR) between 2013 and 2020 and followed up with until March 2022. We used descriptive statistics and modeling to assess temporal trends in new CUC incidence rates and identify factors associated with survival.
Bulgaria's population has decreased by 11.5% between 2011 and 2021. The CUC incidence rate decreased from 29.5/100,000 in 2013 to 23.2/100,000 in 2020 but remains very high. The proportion of patients diagnosed in earlier stages of CUC has decreased over time. Up to 19% of patients with CUC in Bulgaria are diagnosed between the age of 35 and 44 years. The median survival was 101.5 months, with some improvement in later years (adjusted HR = 0.83 for 2017-2020).
In countries with well-established population-based screening, CUC is nowadays considered a rare disease. However, it is not considered rare in Bulgaria. Population-based screening starting at an earlier age is the fastest way to improve outcomes.
在欧洲,东欧的子宫颈癌(CUC)和人乳头瘤病毒(HPV)感染率仍然最高。
本研究的目的是在缺乏基于人群的筛查计划和人口危机的背景下,调查保加利亚的子宫颈癌趋势。
这是一项回顾性研究,对2013年至2020年在保加利亚国家癌症登记处(BNCR)登记并随访至2022年3月的7861例子宫颈癌患者进行了研究。我们使用描述性统计和建模来评估子宫颈癌新发病率的时间趋势,并确定与生存相关的因素。
2011年至2021年期间,保加利亚人口减少了11.5%。子宫颈癌发病率从2013年的29.5/10万降至2020年的23.2/10万,但仍然很高。随着时间的推移,在子宫颈癌早期阶段被诊断出的患者比例有所下降。保加利亚高达19%的子宫颈癌患者是在35至44岁之间被诊断出来的。中位生存期为101.5个月,后期有所改善(2017 - 2020年调整后风险比 = 0.83)。
在拥有完善的基于人群筛查的国家,如今子宫颈癌被认为是一种罕见疾病。然而,在保加利亚并非如此。尽早开始基于人群的筛查是改善治疗效果的最快途径。